1910 Genetics
W19
AI-powered Drug Discovery
Active

1910 Genetics

Make undruggable targets a thing of the past

We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need. We have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. We are currently applying our technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.

Jen Nwankwo, CEO

Founder & CEO @ 1910 Genetics

Jen Nwankwo
Jen Nwankwo
1910 Genetics